SIGA Technologies, Inc. (SIGA)
- Previous Close
8.66 - Open
8.62 - Bid 8.62 x 100
- Ask 8.66 x 200
- Day's Range
8.49 - 8.70 - 52 Week Range
4.22 - 10.00 - Volume
383,207 - Avg. Volume
804,187 - Market Cap (intraday)
614.231M - Beta (5Y Monthly) 0.97
- PE Ratio (TTM)
9.09 - EPS (TTM)
0.95 - Earnings Date Feb 29, 2024 - Mar 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Mar 25, 2024
- 1y Target Est
--
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
www.siga.com45
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: SIGA
Performance Overview: SIGA
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SIGA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SIGA
Valuation Measures
Market Cap
614.23M
Enterprise Value
464.65M
Trailing P/E
9.09
Forward P/E
7.06
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.43
Price/Book (mrq)
3.12
Enterprise Value/Revenue
3.32
Enterprise Value/EBITDA
5.52
Financial Highlights
Profitability and Income Statement
Profit Margin
48.65%
Return on Assets (ttm)
23.26%
Return on Equity (ttm)
37.09%
Revenue (ttm)
139.92M
Net Income Avi to Common (ttm)
68.07M
Diluted EPS (ttm)
0.95
Balance Sheet and Cash Flow
Total Cash (mrq)
150.15M
Total Debt/Equity (mrq)
0.46%
Levered Free Cash Flow (ttm)
85.55M